Peregrine Puts Positive Breast Cancer Trial Data Under Its Belt
This article was originally published in The Pink Sheet Daily
Executive Summary
Data for bavituximab in breast cancer merit further investigation, says company.
You may also be interested in...
New Lung Cancer Data May Offer Reprieve For Peregrine’s Bavituximab
Company releases new analysis of a Phase II second-line lung cancer study that resolves discrepancies that were holding back regulatory progress, now showing a 4.4 month overall survival benefit for first-in-class bavituximab. Peregrine is now gearing up for a Phase III study at the end of 2013.
Genentech Restricts Population In Last-Ditch Bid To Keep Avastin’s Breast Cancer Claim
Genentech’s last-ditch bid to retain Avastin’s metastatic breast cancer claim expands upon discussions at FDA’s June 28-29 hearing about targeted subpopulations and labeling revisions, but breaks little new ground.
Troubled Biotechs Revisited: Peregrine Placing All Of Its Chips On Bavituximab
The story doesn’t end once a company is profiled in our periodic “troubled biotechs” roundups – here we check back in on three firms.